• Roche Enlists Dyno to Bring AI to Next-Generation Liver, CNS Gene Therapies

    5 days ago - By Xconomy

    Roche made a splash with its acquisition of Spark Therapeutics, whose Luxturna, a gene therapy for an inherited form of vision loss, was the first such therapy to win FDA approval. Now the Swiss pharmaceutical giant is looking to bolster its capabilities in liver and central nervous system disorder gene therapies and it's turning to Dyno Therapeutics to help. Dyno, a two-year-old startup based in Cambridge, MA, has never brought a gene therapy to the market, nor does it currently have its own drug pipeline. What it does have is a platform technology for engineering the viruses that ferry...
    Read more ...